GlassScriptPhysician profile
Alejandra Perez
NPI 1124510862
$9,782.83
in general payments reported to CMS, 2019-2025
24 companies · $2,480 in 2025
The $2,480 reported for 2025 was more than what 84% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $46.12 · 2021: $37.99 · 2022: $150 · 2023: $2,591 · 2024: $4,239 · 2025: $2,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,101 · Travel and Lodging: $3,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,100.97 |
| Travel and Lodging | $3,209.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $3,567.82 | 2023-2025 | Titan |
| Boston Scientific Corporation | $2,375.81 | 2019-2025 | Lumenis Pulse 120h, Tactra, Ams 700 |
| Procept Biorobotics Corporation | $1,451.85 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Edap Technomed INC | $283.46 | 2023 | |
| Blue Earth Diagnostics | $225.43 | 2023-2024 | |
| Olympus America INC. | $183.18 | 2025 | Soltive, Gyrus Acmi, Uropass |
| Teleflex LLC | $171.89 | 2023 | Urolift |
| Axonics, INC. | $166.06 | 2023-2024 | Axonics, Bulkamid |
| Urogen Pharma, INC. | $147.99 | 2023 | Jelmyto |
| Immunitybio, INC. | $146.32 | 2025 | |
| Astellas Pharma US INC | $134.76 | 2019 | |
| Pfizer INC. | $132.59 | 2021-2023 | |
| Biotissue Holdings INC. | $125.00 | 2023 | |
| Janssen Biotech, INC. | $121.81 | 2024 | Erleada, Akeega |
| Ambu INC. | $117.83 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $105.41 | 2023 | |
| Merck Sharp & Dohme LLC | $86.62 | 2020-2022 | |
| Kulzer, LLC | $54.87 | 2025 | |
| Tolmar, INC. | $46.81 | 2023 | |
| Myriad Genetic Laboratories, INC. | $35.24 | 2023 | Prolaris |
| Sumitomo Pharma America, INC. | $34.65 | 2023 | Gemtesa |
| Convatec INC. | $33.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.06 | 2024 | |
| Pharmaand Gmbh | $12.84 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandra Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.